Source:http://linkedlifedata.com/resource/pubmed/id/17352386
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2007-7-12
|
| pubmed:abstractText |
The use of 5-aminosalicylate (5-ASA) drugs in Crohn's disease (CD) is controversial, with their continuing apparent widespread use despite high-level evidence indicating marginal benefit at best and international guidelines recommending limited indications.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1078-0998
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1009-15
|
| pubmed:meshHeading | |
| pubmed:year |
2007
|
| pubmed:articleTitle |
5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists.
|
| pubmed:affiliation |
Monash University Department of Medicine and Department of Gastroenterology, Box Hill Hospital, Box Hill, Victoria, Australia.
|
| pubmed:publicationType |
Journal Article
|